Compare ACRS & SPIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | SPIR |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.5M | 826.5M |
| IPO Year | 2015 | 2020 |
| Metric | ACRS | SPIR |
|---|---|---|
| Price | $5.93 | $11.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $10.20 | ★ $16.40 |
| AVG Volume (30 Days) | ★ 1.8M | 547.0K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 69.01 | ★ 134.98 |
| EPS | ★ N/A | N/A |
| Revenue | $1,683,000.00 | ★ $110,451,000.00 |
| Revenue This Year | N/A | $12.31 |
| Revenue Next Year | $4.24 | $22.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 13.15 |
| 52 Week Low | $1.74 | $6.60 |
| 52 Week High | $6.60 | $25.93 |
| Indicator | ACRS | SPIR |
|---|---|---|
| Relative Strength Index (RSI) | 50.42 | 36.12 |
| Support Level | $5.64 | $11.62 |
| Resistance Level | $6.56 | $15.07 |
| Average True Range (ATR) | 0.31 | 0.79 |
| MACD | -0.05 | -0.19 |
| Stochastic Oscillator | 33.34 | 13.00 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Spire Global Inc provides space-based data, analytics, and space services, offering datasets and insights about Earth to support decision-making. It builds, owns, and operates a constellation of nanosatellites that observe the Earth in real time using radio frequency (RF) technology. Additionally, it offers Space Services solutions that allow customers to deploy and scale their own satellite constellations using its platform, ground station network, manufacturing facilities, and launch partnerships. The company derives revenue from providing data, insights and access to its cloud-based technology platform sold on a subscription basis.